Oct. 27 at 10:02 AM
                            
$PGEN Novartis has announced the acquisition of Avidity for approximately 
$12 billion, integrating these programs into its neuromuscular portfolio. But the drugs remain experimental and have not yet been approved by the FDA. Furthermore, they are for patients with rare genetic diseases. So, what could 
$PGEN Precigen be worth with a billion-dollar drug approved, the rest of its pipeline, and its innovative and powerful platform?